News Digest / Ticker: INKT

Ticker: INKT

08:29am, Friday, Jul 11, 2025

MiNK Therapeutics Soars 200% on Promising Clinical Trial Results: Is This the Next Hidden Gem in Oncology?

MiNK Therapeutics (NASDAQ: INKT) saw a 200% stock surge after positive clinical trial results for its agenT-797 therapy in metastatic testicular cancer. The treatment led to complete remission in a patient resistant to prior therapies and boasts a favorable safety profile. Investors should watch ...

05:09pm, Thursday, May 15, 2025

MiNK Therapeutics Faces Financial Strain Despite Promising Clinical Trial Progress and Cost Reductions